Hit-to-Lead Candidate

Our partnership’s combined offerings will leverage Mabqi’s LiteMab Antibody Discovery Studio for hit screening, characterization, and hit selection by using universal & pH-sensitive libraries to identify top lead candidates, and utilize Abzena’s capabilities for developability, cell line development, process development, and GMP manufacturing. Both organizations have extensive expertise in supporting a broad range of modalities, including monoclonal antibodies (mAbs), mAb fragments, bi- and multi-specifics, and bioconjugates such as AOCs.

We provide our customers with a unique ecosystem of premium expert support through our DRIVE-Biologics collaboration with Oncodesign Services.  DRIVE-Biologics leverages the skills and expertise to develop antibodies in oncology and inflammation through a privileged collaboration that combines Abzena’s discovery, development, and manufacturing support of biologics and ADCs with Oncodesign Services of optimization to lead selection of naked or pay-loaded preclinical candidates vs TPP.

For more information about this streamlined collaboration, click here.